GlassScriptPhysician profile
Amy Amoroso
NPI 1073185047
$3,207.21
in general payments reported to CMS, 2019-2025
25 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $559 · 2023: $799 · 2024: $850 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.13 |
| Education | $106.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $844.03 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $341.35 | 2022-2025 | |
| Amgen INC. | $317.63 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $256.67 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.01 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $194.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $190.16 | 2023-2025 | Veozah |
| Pfizer INC. | $185.86 | 2023-2025 | |
| Abbvie INC. | $89.27 | 2023 | |
| Inspire Medical Systems, INC. | $87.73 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $73.14 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $71.09 | 2022-2023 | Airduo Digihaler |
| Idorsia Pharmaceuticals US INC | $47.97 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $36.63 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $35.20 | 2024-2025 | Zenpep |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.89 | 2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $23.85 | 2022 | |
| Tactile Systems Technology INC | $22.90 | 2023 | Flexitouch Plus, Entre Plus |
| Exeltis, USA INC. | $20.83 | 2023 | Slynd |
| Novartis Pharmaceuticals Corporation | $20.11 | 2025 | |
| Mimedx Group, INC. | $19.85 | 2025 | |
| Xeris Pharmaceuticals, INC. | $18.99 | 2022 | |
| Cleerly, INC. | $16.34 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.51 | 2024 | Caplyta |
| Medicure Pharma INC. | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Amoroso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.